Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis-Reference-Cited by-同舟云学术

Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis

Published:2009-01 Issue:1 Volume:7 Page:11-19
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Chu David,Lacouture Mario E.,Weiner Elizabeth,Wu Shenhong

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference37 articles.

1. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer;Abrams;Mol Cancer Ther,2003

2. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model;Murray;Clin Exp Metastasis,2003

3. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo;O'Farrell;Blood,2003

4. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels;Osusky;Angiogenesis,2004

5. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models;Schueneman;Cancer Res,2003

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings;Human Pathology;2023-10

2. Dermatologic Complications of Cancer Chemotherapy;Holland‐Frei Cancer Medicine;2022-10-21

3. The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis;Tumori Journal;2022-05-04

4. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2021-10-14

5. How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs;Journal of Oncology Pharmacy Practice;2021-04-19